Itherx Raises $2.8M in Debt

Bruce V. Bigelow

Itherx Pharmaceuticals, a San Diego biotech known until 2007 as Immusol, has raised almost $2.8 out of a planned debt offering of $3 million, according to a recent regulatory filing. The company, which became Itherx when Jeffrey McKelvy, was named president and CEO, says it is developing innovative treatments for Hepatitis C. The company’s chief scientific officer is Flossie Wong-Staal, an acclaimed molecular biologist at UCSD who is recognized for her role in identifying HIV as the cause of AIDS.